HCV and HCC Tango—Deciphering the Intricate Dance of Disease: A Review Article

Milosevic, Ivana; Todorovic, Nevena; Filipovic, Ana; Simic, Jelena; Markovic, Marko; Stevanovic, Olja; Malinic, Jovan; Katanic, Natasa; Mitrovic, Nikola; Nikolic, Natasa

doi:10.3390/ijms242216048

Cited by 3 publications

(1 citation statement)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C virus is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [19]. The nonstructural protein (NS3) helicase of HCV, which is crucial for viral replication, holds promise as a target for novel antiviral drugs.…”

Section: Hcv and Hbvmentioning

confidence: 99%

Effects of Marine Natural Products on Liver Diseases

Sun,

Dong,

Cui

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

The prevention and treatment of liver disease, a class of disease that seriously threatens human health, has always been a hot topic of medical research. In recent years, with the in-depth exploration of marine resources, marine natural products have shown great potential and value in the field of liver disease treatment. Compounds extracted and isolated from marine natural products have a variety of biological activities such as significant antiviral properties, showing potential in the management of alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), protection of the liver from fibrosis, protection from liver injury and inhibition of the growth of hepatocellular carcinoma (HCC). This paper summarizes the progress of research on marine natural products for the treatment of liver diseases in the past decade, including the structural types of active substances from different natural products and the mechanisms underlying the modulation of different liver diseases and reviews their future prospects.

show abstract

Section: Hcv and Hbvmentioning

confidence: 99%

Effects of Marine Natural Products on Liver Diseases

Sun,

Dong,

Cui

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

show abstract

Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development

Todorovic,

Martinelli,

Nannini

et al. 2024

IJMS

View full text Add to dashboard Cite

Chronic liver disease is characterised by persistent inflammation, tissue damage, and regeneration, which leads to steatosis, fibrosis, and, lastly, cirrhosis and hepatocellular carcinoma (HCC). HCC, the most prevalent form of primary liver cancer, is one of the leading causes of cancer-related mortality worldwide. The gut microbiota plays a fundamental role in human physiology, and disturbances in its critical balance are widely recognised as contributors to various pathological conditions, including chronic liver diseases, both infectious and non-infectious in nature. Growing interest in microbiota research has recently shifted the focus towards the study of intratumoural microbiota, referred to as the “oncobiome”, which can significantly impact the development and progression of HCC. In this review, we discuss existing research and provide an overview of the microbiota influence on viral hepatitis, particularly in shaping the progression of liver disease caused by the hepatitis B and hepatitis C viruses. We also explore microbial dysbiosis and its contribution to the silent and dangerous progression of non-alcoholic fatty liver disease. Additionally, we address the impact of alcohol on the liver and its interaction with the microbiota, tracing the pathway from inflammation to cirrhosis and cancer. The review emphasises the most common etiologies of hepatocellular carcinoma.

show abstract

HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12

Milošević,

Beronja,

Filipović

et al. 2024

Microorganisms

View full text Add to dashboard Cite

People who inject drugs (PWIDs) experience high rates of hepatitis C virus (HCV) infection, primarily due to needle sharing and limited healthcare access, resulting in a disproportionate disease burden within this population. This prospective study evaluated treatment outcomes in 432 adult patients with chronic hepatitis C (CHC) treated with direct-acting antivirals (DAAs) at the University Clinical Center of Serbia. Patients were categorized into two groups based on a history of drug addiction: PWIDs (163, 37.7%) and non-PWIDs (269, 62.3%). The PWID group was further categorized into subpopulations of problematic PWIDs (39, 23.9%), ex-PWIDs (124, 76.1%), and PWIDs on OST (96, 58.9%). The PWID group demonstrated significantly lower treatment adherence, with an intention-to-treat (ITT) rate of 82.8%, compared to 96.3% in the control group (p < 0.001). In contrast, no significant differences were observed in per-protocol (PP) outcomes between the two groups. Additionally, PWIDs were significantly younger (p < 0.001) and had higher rates of psychiatric disorders (p < 0.001), alcohol abuse (p < 0.001), and HCV genotype 1a (p < 0.001). Advanced fibrosis was predictor of PP treatment failure among PWIDs, while mood disorders and alcohol use disorder were associated with interruptions before the scheduled completion time. For non-PWIDs, older age and advanced fibrosis emerged as key predictors of PP treatment failure. The loss to follow-up was most commonly observed in the problematic PWID subgroup (p = 0.001). These findings highlight the importance of addressing barriers in PWIDs through integrated care strategies that concurrently manage addiction and HCV.

show abstract

HCV and HCC Tango—Deciphering the Intricate Dance of Disease: A Review Article

Cited by 3 publications

References 192 publications

Effects of Marine Natural Products on Liver Diseases

Effects of Marine Natural Products on Liver Diseases

Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development

HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12

Contact Info

Product

Resources

About